Just a bit of information about the manufacturers of
Endostatin/Angiostatin and some things to ponder. I hope you are all
having a great day.
Take care and God Bless
marty auslander
COMPANY'S STOCK SOARS ON NEWS OF CANCER DRUG
The stock of a company developing a new cancer treatment leaped
$12.00 per share to $85.00 per share at one point Monday, even while
doctors cautioned against getting too excited over something that has
been tested only on mice.
The article and the resulting publicity had a stunning effect on the
stock of Entremed, Inc, the Rockville, MD company founded to develop
angiodstatin and endostatin.
Among some of the questions to be answered:
# Can angiostatin and endostatin, which are normal proteins, be
duplicated through gene splicing? Scientists say these are large
proteins and so are technically difficult to make. The company hopes to
have enough for human testing in 12 to 18 months.
#Will humans be able to tolerate them? Interleuken-2, which mice cold
stand in large doses, turned tou to be toxic in peopl and has to be used
sparingly. Although this is not the typical chemotherapy.
# Will the drugs have side effects that make them hazardous when given
for many years, as some envision them being used?
# What happens to the bodys ability to heal wounds? Presumably, anything
that stops new blood vessel growth would also block this vital process.
On a positive Side: Several others drugs aimed at blocking blood
vessels have already entered early stages of human testing, and
researchers said that perhaps 50 in all are in various stages of
development.
Orange County Register dtd 4/11/98
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
